**DRUG:** SURFACTANT (BOVINE) – BERACTANT (SURVANTA)

**PRESENTATION:**
Vial: 8 mL

**ACTION & INDICATION:**
Pulmonary surfactant derived from natural bovine lung extract and used for the prevention or treatment of respiratory distress syndrome, according to NCCU guidelines.

**DOSE:**
4 mL/kg/dose
Up to four doses may be administered, at 6 hourly intervals.

**ADMINISTRATION:**
For intratracheal administration only.
Survanta is administered via a 5fg end hole catheter shortened to protrude just beyond the end of the ETT, above the carina. Survanta should NOT be instilled into a main stem bronchus.
Administer as outlined in the NCCU “Surfactant Replacement Therapy Guidelines”.

**ADVERSE EFFECTS:**
Adverse effects associated with dosing procedure:
Transient bradycardia, oxygen desaturation, ETT reflux, pallor, vasoconstriction, hypotension, ETT blockage, hypertension, hypocarbica, hypercarbica, apnoea.

**COMMENTS:**
Warm vial to room temperature before use. Do not use artificial warming methods. Do not shake.
Store open and unopened vials at 2 - 8ºC.
Discard 12 hours after opening.
Evaluate clinical condition before and for 30 minutes after each dose.

**REFERENCES:**
Neofax 2013

**DATE:**
October 2013